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Relationship of apelin, procalcitonin, and fetuin-A
concentrations with carotid intima-media thickness
in acromegaly
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Abstract
Background: Acromegaly is characterized by excess growth hormone and insulin-like growth factor-1 concentrations.
There is conflicting evidence as to whether acromegaly is associated with an increased risk of atherosclerosis. Apelin is an
adipose tissue-derived peptide that may be associated with hyperinsulinemia. Fetuin-A is a hepatocyte produced plasma
glycoprotein that has an important role as a calcification inhibitor. The aim of this study was to examine apelin, fetuin-A,
and procalcitonin concentrations and to assess their relationship with carotid intima medial thickness (cIMT) in subjects
with acromegaly.
Methods: Apelin, fetuin-A, and procalcitonin serum concentrations were measured in 37 (20 inactive and 17 active)
subjects with acromegaly and 30 control subjects, along with carotid intima medial thickness.
Results: The concentrations of apelin, fetuin-A, and procalcitonin were increased in subjects with acromegaly. There
were significant correlations between apelin, fetuin-A, and procalcitonin in subjects with acromegaly. Carotid intima
medial thickness values were similar between control subjects and subjects with acromegaly.
Conclusions: Carotid intima medial thickness was not increased in subjects with acromegaly. It is possible that the
increased apelin and fetuin-A concentrations observed play a protective role against the development of atherosclerosis
in subjects with acromegaly.
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Introduction
Acromegaly is an uncommon chronic disorder charac-
terized by classical clinical features caused by excess
growth hormone (GH) and consequent raised concen-
trations of insulin-like growth factor-1 (IGF-1). This
condition may be associated with increased morbidity
and mortality, considered to be mainly due to cardio-
cerebrovascular disease (although the latter is unclear).1
In most cases, acromegaly is caused by a pituitary
somatotroph adenoma that secretes excess GH, which
leads to insulin resistance, glucose intolerance, and
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increased prevalence rates of atherosclerosis and car-
diovascular mortality.1,2 The presence of early athero-
sclerotic changes may be assessed by measuring carotid
intima medial thickness (cIMT) with carotid Doppler
ultrasonography (USG).3–5
Apelin and the APJ (apelin) receptor are expressed
in a wide variety of tissues, including heart, brain, kid-
neys, and lungs.6–9 Apelin is a peptide growth factor
that exhibits high aﬃnity binding with the APJ recep-
tor, which has high sequence homology with the angio-
tensin II type 1 receptor, but does not bind angiotensin
II.10,11 Procalcitonin and fetuin-A are proteins that are
mainly secreted by the liver.12,13 Procalcitonin secretion
is closely related to inﬂammatory mediator concentra-
tions,12 while fetuin-A inhibits arterial calcium depos-
ition in vitro.13 Clinical studies have demonstrated that
circulating fetuin-A concentrations are positively asso-
ciated with fat accumulation in the liver, insulin resist-
ance, and metabolic syndrome.14–16
Data on accelerated atherosclerosis and increased
cardiovascular risk in acromegaly are somewhat con-
ﬂicting and have been based for the most part on retro-
spective case series reports.17,18 The aim of this study
was to examine apelin, procalcitonin, and fetuin-A con-
centrations and assess their relationship with cIMT in
subjects with acromegaly.
Material and methods
This study was approved by the institutional ethics and
research committee of Pamukkale University. Informed
consent was obtained from all participants.
Measurements were performed in 37 acromegalic
patients (20 male and 17 female) and 30 healthy con-
trols (15 male and 15 female). The mean ages of the
patient and controls were similar (51.5 y 10.5 and
46.4 6.9, respectively, P> 0.05).
Height and weight were measured with participants
wearing light clothes and no shoes, and body mass
index (BMI) was calculated as weight (kg)/height
(m)2. Systolic and diastolic blood pressures were mea-
sured twice in the seated position after 5min of rest.
Serum insulin, thyroid stimulating hormone (TSH),
GH, and IGF-I concentrations were measured by
chemiluminescent assay (Immulite 2000, Siemens AG,
Erlangen, Germany). Serum concentrations of glucose,
triglyceride, HDL-cholesterol, and LDL-cholesterol
were measured on a Beckman-Coulter LX-20 analyzer
(Beckman-Coulter Inc., Brea, CA, USA), with reagents
supplied by the manufacturer.
Acromegaly subjects with GH41 mg/L and IGF-1
concentrations within the healthy population reference
ranges appropriate for age and sex were classiﬁed as
‘‘inactive,’’ and patients with GH>1 mg/L, and higher
IGF-1 concentrations, were classiﬁed as having
‘‘active’’ acromegaly. Insulin resistance was calculated
according to the homeostasis model assessment
(HOMA) method, using the following formula: (fasting
plasma insulin [mIU/L fasting plasma glucose
(mmol/L)]/ 22.5. A HOMA-IR cutoﬀ value >2.7 is con-
sidered to indicate insulin resistance.
Blood samples were obtained by venepuncture
between 8:00 and 10:00 am after a 12 h fast. Plasma
total cholesterol, triglycerides, HDL, LDL, TSH, GH,
IGF-1, IGFBP3, insulin, and glucose concentrations
were measured immediately. Serum samples for
apelin, procalcitonin, and fetuin-A measurement
were frozen at 80C until analysis (RayBio Human
Apelin kit, RayBiotech, Norcross, GA, USA; Booster
Human Fetuin-A kit, RayBiotech, Norcross, GA,
USA; CUSABIO Human Procalcitonin kit, CSB-
E09502h, CUSABIO, Hubei, China) according to the
manufacturers’ instructions. The intra-assay and inter-
assay coeﬃcients of variation (%CV) varied between
10–15% (apelin), 10–12% (fetuin-A), and <8–<10%
for (procalcitonin).
B-mode USG of the left and right common and
internal carotid arteries was performed with measure-
ments made at least 15min after resting in a supine
position. After bilateral, longitudinal, and transverse
examination of the carotid arteries, two sets of standar-
dized images were obtained at 5-min intervals at two
diﬀerent points: one at the lateral angle of the carotid
artery bulb and 20mm proximal to the bifurcation. The
common cIMT was calculated as the mean of the left
and right measurements, and cIMT values >0.8mm
were considered as increased thickness.
Statistical analysis was done with SPSS (Statistical
Package for Social Sciences) 13.0 software (SPSS Inc,
Chicago, IL, USA). Discrete variables were expressed
as counts (percentage) and interquartile ranges. In the
statistical evaluations, one-way analysis of variance test
was used to observe any diﬀerences between control
group, active acromegaly, and inactive acromegaly sub-
ject groups. In the determination of diﬀerent groups,
Duncan multiple comparison method was used. The
Bonferroni–Dunn procedure was used to compare
mean values between the groups. In addition, logistic
regression and Pearson’s correlation tests were used for
association between parameters. All testing was two-
tailed and p values less than 0.05 were considered to
indicate statistical signiﬁcance.
Results
The clinical and demographical ﬁndings of control,
active, and inactive acromegaly subject groups are
shown (Table 1). Higher apelin, procalcitonin, and
fetuin-A concentrations were observed in subjects
with acromegaly compared to controls. Notably, the
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procalcitonin concentrations in subjects with acromeg-
aly were found to be almost sevenfold higher than con-
trols (P< 0.0001). There were no diﬀerences in apelin,
fetuin-A, or procalcitonin concentrations between the
active and inactive acromegaly groups, and both
groups exhibited similar cIMT measurements.
Statistically signiﬁcant correlations were observed
for apelin, fetuin-A, and procalcitonin concentrations
in subjects with acromegaly (Table 2). In particular,
positive correlations were found between the concentra-
tions of apelin and GH, fetuin-A and IGF-1, and pro-
calcitonin and BMI. There were no signiﬁcant
associations of apelin, fetuin-A, or procalcitonin with
HOMA or with IGFBP3, triglyceride, LDL, HDL, or
total cholesterol concentrations.
Discussion
The physiological importance of fetuin-A, procalcito-
nin, and apelin concentrations in acromegaly has been
unclear. The present study found higher concentrations
of fetuin-A, procalcitonin, and apelin in subjects with
acromegaly but no increase in cIMT.
Acromegaly-related symptoms are usually asso-
ciated with metabolic and cardiovascular complica-
tions, such as obesity, hypertriglyceridemia, diabetes
mellitus, and hypertension, all of which may confer
increased risk of atherosclerosis. Studies of acromegaly
have reported diﬀering ﬁndings regarding the relation-
ship with atherosclerosis.19–21 Fetuin-A, a liver-derived
inhibitor of calciﬁcation, has been inversely associated
with arterial stiﬀness and cardiovascular morbidity and
mortality.22 Prospective studies have suggested that low
serum fetuin-A concentrations may be a predictor of
coronary artery disease incidence, severity, and related
mortality.23–25 The cardioprotective role of fetuin-A
has been supported by low circulating fetuin-A concen-
tration as a negative predictor of acute coronary disease
evolution.25 Insulin resistance in acromegaly causes
impaired glucose tolerance and type 2 diabetes in 60
and 25% of patients, respectively.26 Studies performed
in laboratory animals and humans suggested that
Table 1. Characteristics of subjects with inactive acromegaly, active acromegaly, and controls. Results given as median (interquartile
range).
Inactive (n¼ 20) *P Active (n¼ 17) Controls (n¼ 30) **P
Ages (years) 55.2 (48.8–63.3)a NS 47.1 (37–55)b 46.4 (41.3–51)b <0.01
Height (cm) 167.2 (158–174) NS 168.1 (161–172) 167.4 (164–172) NS
Weight (kg) 81.7 (75–91.3)a NS 84.6 (75–90)a 71.5 (60.5–81.8)b <0.01
BMI (kg/m2) 29.5 (25.8–33.3)a NS 29.2 (27.3–31.1)a 25.4 (22.5–27.7)b <0.01
Systolic BP (mmHg) 136 (130–140)a NS 132.4 (130–140)a 119.3 (100–130)b <0.01
Diastolic BP (mmHg) 81.5 (80–80)ab NS 82.9 (80–90)a 76 (70–80)b <0.05
Fasting glucose (mmol/L) 6.1 (5.3–6.4)a NS 6.4 (5.2–6.9)a 5.3 (4.9–5.5)b <0.01
Creatinine (mmol/L) 61.9 (54.8–69)ab NS 57.5 (46.9–67.2)a 69.8 (59.2–84)b <0.05
Total cholesterol (mmol/L) 4.8 (3.2–5.6) NS 4.9 (4.2–5.4) 5.2 (4.6–5.6) NS
Triglyceride (mmol/L) 1.1 (0.7–1.4)a <0.01 1.7 (0.9–2.4)b 1.4 (0.8–1.7)ab <0.05
HDL (mmol/L) 1.5 (1.2–1.7) NS 1.4 (1.2–1.5) 1.4 (1.1–1.7) NS
LDL (mmol/L) 2.8 (2.1–3.4) NS 2.8 (2.0–3.3) 3.2 (2.6–3.7) NS
GH (mg/L) 0.8 (0.5–0.9)a <0.01 2 (1.3–2.3)b 0.4 (0.1–0.2)c <0.001
IGF1 (ug/L) 216.1 (162–278.3)a <0.05 414.4 (318–500)b 151.4 (117–182.3)c <0.001
IGFBP3 (mg/L) 4.5 (4.1–5.4)a <0.05 5.6 (4.9–6.5)b 4.2 (3.6–4.7)a <0.01
Insulin (pmol/L) 41 (21.3–68.6) NS 56.7 (35.8–84.2) 81.1 (45.3–70.1) NS
Right cIMT (mm) 0.7 (0.7–0.8) NS 0.7 (0.7–0.8) 0.8 (0.6–0.8) NS
Left cIMT (mm) 0.8 (0.7–0.9) NS 0.8 (0.7–0.9) 0.8 (0.6–0.8) NS
Apelin (nug/L) 121.5 (95.1–149.2)a NS 116.5 (94.1–132.3)a 99.6 (88–113.7)b <0.05
Fetuin-a (ug/L) 1.9 (1–2)a NS 2.6 (1.2–4.2)a 1.1 (0.6–1.3)b <0.001
Procalcitonin (ug/L) 79.5 (36.5–117.1)a <0.05 59.1 (39.6–85.1)a 10.6 (–1.8–22.2)b <0.001
HOMA-IR 1.7 (0.6–1.9) NS 2.2 (1.2–2.7) 2.6 (1.4–2) NS
*P value (Bonferroni–Dunn Test) between inactive and active and acromegalic subjects.
**P value for one-way ANOVA of results from inactive and active acromegaly subjects and control subjects.
aSignificant with respect tob and/orc.
bSignificant with respect toa and/orc.
cSignificant with respect toa and/orb.
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fetuin-A induces insulin resistance,27–30 which supports
the hypothesis that fetuin-A may also play a role in the
pathophysiology of acromegaly. However, the relation-
ship of fetuin-A to insulin resistance is still a subject
of debate and the physiological importance of fetuin-A
in acromegaly remains unclear. Our results show
that although fetuin-A concentration was increased in
subjects with acromegaly there was no correlation
between fetuin-A concentration and insulin resistance
or cIMT. This ﬁnding supports the suggestion that
high serum fetuin-A concentration may have a protect-
ive eﬀect against artherosclerosis. The putative protect-
ive action of fetuin-A may act through a direct
antiatherogenic eﬀect or through an anti-inﬂammatory
action. To our knowledge, this is the ﬁrst study for to
examine serum fetuin-A concentrations in acromegaly.
A limitation of our study is the relatively small
number of subjects with acromegaly included and
therefore the ﬁndings need to be conﬁrmed in a larger
study.
The functions of apelin and its receptor are not fully
understood. Various studies have suggested that apelin
is involved in body ﬂuid homeostasis31 and cardiovas-
cular system regulation.32,33 It is well known that bone
mineral disorders and the related vascular calciﬁcation
plays an important role in the pathogenesis of cardio-
vascular disease. It has been proposed that apelin is
protective against vascular calciﬁcation through
inhibition of osteoblastic diﬀerentiation of vascular
smooth muscle cells.34 However, the role of the
apelin–APJ system in cardiovascular function and its
relationships to other neuroendocrine pathways
remain unclear.35 Apelin injection resulted in improved
cardiac function and reduced cardiac loading in vivo.36
Serum apelin concentrations were found to be lower in
uremic patients with dilated cardiomyopathy.37 Lower
apelin concentrations in patients with both chronic
kidney disease and heart disease than those with
chronic kidney disease without heart disease have
been reported.37,38 In the present study, we found
higher apelin concentrations in subjects with acromeg-
aly than in controls and a signiﬁcant correlation with
GH concentration in these subjects. There was no cor-
relation with between apelin concentration and cIMT.
One possible explanation for these associations is that
high apelin concentrations may play a protective role
against the development of atherosclerosis.
There is conﬂicting evidence as to whether subjects
with acromegaly are at increased risk of accelerated
atherosclerosis. Cannavo et al.39 reported that 41% of
subjects with acromegaly were at risk of coronary ath-
erosclerosis and furthermore Ozkan et al.40 found that
procalcitonin can be used as a marker of premature
atherosclerosis. In contrast, Bogazzi et al.41 showed
that coronary heart disease risk of in acromegaly was
lower than that in subjects without acromegaly.
Although our study conﬁrms the ﬁnding of increased
procalcitonin concentration there was no correlation
with cIMT.
GH increases glucose production and inhibits hep-
atic gluconeogenesis, and excessive GH production
leads to compensatory hyperinsulinemia.42 In the pre-
sent study, we noted statistically signiﬁcant diﬀerences
between subjects with acromegaly and controls for
body weight, systolic and diastolic blood pressures,
fasting glucose, and LDL concentrations (Table 1).
In conclusion, we found increased serum concentra-
tions of fetuin-a, procalcitonin, and apelin in subjects
with acromegaly and positive correlations between
apelin and GH, fetuin-A and IGF-1, and procalcitonin
and BMI. cIMT was not increased in the subjects with
acromegaly despite having higher procalcitonin. We
speculate that the higher concentrations of fetuin-A
and apelin may play a protective role against cardio-
vascular disease in subjects with acromegaly.
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Table 2. Correlations between apelin, fetuin-A, procalcitonin,
GH, IGF-1 concentrations and BMI in subjects with acromegaly.
Apelin Fetuin-a Procalcitonin
Apelin (ug/L)
r 1 0.337 0.507
p 0.006** 0.000**
Fetuin-a (ug/L)
r 0.337 1 0.548
p 0.006** 0.000**
Procalcitonin (ug/L)
r 0.507 0.548 1
p 0.000** 0.000**
GH (mg/L)
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BMI (kg/m2)
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**Correlation is significant at the 0.01 concentration.
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